Plant ID: NPO3868
Plant Latin Name: Senecio sinuatus
Taxonomy Genus: Senecio
Taxonomy Family: Asteraceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
GPR35; | |
RECQL; TDP1; HSD11B1; AKR1B10; HPGD; AKR1B1; APEX1; POLB; | |
CDC25B; | |
TEK; INSR; MET; EGFR; NUAK1; SRC; KDR; IGF1R; CSNK2A1; | |
RORC; | |
NR1H4; | |
KDM4E; | |
FUT7; | |
SLC22A6; SLCO1B3; | |
SMAD3; LMNA; HSPA1A; |
Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 3.042E-10 | 6.623E-06 | EGFR, IGF1R, INSR, KDR, MET, TEK |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 6.456E-09 | 1.354E-05 | EGFR, IGF1R, INSR, KDR, SRC |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.321E-08 | 1.797E-05 | AKR1B1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, LMNA, NR1H4, SMAD3, SRC, TEK |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.278E-07 | 1.908E-04 | EGFR, INSR, KDR |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.109E-06 | 5.751E-04 | EGFR, IGF1R, INSR, KDR, TEK |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.026E-06 | 8.485E-04 | APEX1, POLB |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.399E-06 | 9.673E-04 | EGFR, INSR, MET, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 3.019E-06 | 1.114E-03 | AKR1B1, APEX1, CSNK2A1, EGFR, HPGD, INSR, SRC, TEK |
MF | GO:0005488; binding | GO:0005524; ATP binding | 3.196E-06 | 1.160E-03 | CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, RECQL, SRC, TEK |
BP | GO:0009987; cellular process | GO:0007169; transmembrane receptor protein tyrosine kinase signaling pathway | 5.443E-06 | 1.659E-03 | EGFR, IGF1R, INSR, KDR, MET, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 6.166E-06 | 1.721E-03 | APEX1, CSNK2A1, EGFR, HPGD, RORC, SLC22A6, SRC, TEK |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 6.441E-06 | 1.775E-03 | EGFR, HPGD, SLC22A6, SLCO1B3, TEK |
BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 1.108E-05 | 2.774E-03 | AKR1B1, APEX1, IGF1R, INSR, SRC |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.706E-05 | 3.607E-03 | AKR1B1, APEX1, EGFR, SRC |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.281E-05 | 4.342E-03 | AKR1B1, APEX1, CDC25B, CSNK2A1, HPGD, HSPA1A, LMNA, NR1H4, NUAK1, POLB, RECQL, RORC, SMAD3, SRC |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 2.440E-05 | 4.580E-03 | EGFR, INSR, KDR, SMAD3, SRC |
MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 2.501E-05 | 4.638E-03 | AKR1B1, AKR1B10, HPGD, HSD11B1 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 2.802E-05 | 5.002E-03 | EGFR, INSR, SMAD3 |
MF | Unclassified; | GO:0004872; receptor activity | 3.780E-05 | 6.189E-03 | EGFR, GPR35, HPGD, IGF1R, INSR, KDR, MET, NR1H4, RORC, TEK |
BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 4.236E-05 | 6.733E-03 | EGFR, POLB |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 4.777E-05 | 7.483E-03 | AKR1B1, APEX1, EGFR, KDR, SRC |
BP | GO:0008152; metabolic process | GO:0044598; doxorubicin metabolic process | 5.643E-05 | 8.359E-03 | AKR1B1, AKR1B10 |
BP | GO:0008152; metabolic process | GO:0044597; daunorubicin metabolic process | 5.643E-05 | 8.359E-03 | AKR1B1, AKR1B10 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 6.804E-05 | 9.559E-03 | EGFR, IGF1R, INSR |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.621E-27 | 1.197E-24 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA4, CA7, CA6, CA9, CA14, CA13 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.490E-15 | 1.170E-13 | PTPN1, SMAD3, CSNK2A1, SRC, INSR, ERBB2, ACP1, MET, PTPRF, EGFR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.171E-12 | 2.706E-10 | PDGFRB, GSK3B, SRC, FLT4, ERBB2, KDR, AKT1, BRAF, MET, PTK2, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.742E-10 | 6.838E-09 | PDGFRB, SRC, INSR, FLT4, KDR, AKT1, BRAF, TEK, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 6.367E-09 | 1.999E-07 | PDGFRB, PLA2G1B, INSR, FLT4, KDR, AKT1, TEK, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.658E-08 | 4.638E-07 | PDGFRB, GSK3B, INSR, FLT4, KDR, AKT1, TEK, MET, PTK2, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.596E-08 | 4.638E-07 | PDGFRB, GSK3B, ERBB2, AKT1, BRAF, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.647E-08 | 5.726E-07 | SRC, ERBB2, KDR, AKT1, BRAF, MET, PTK2, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.214E-08 | 4.638E-07 | GSK3B, SRC, ERBB2, AKT1, BRAF, EGFR, PTK2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.065E-08 | 4.638E-07 | PLK4, SMAD3, INSR, PLK1, AKT1, BRAF, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 2.553E-07 | 3.341E-06 | PDGFRB, DUSP3, AKT1, BRAF, MAP3K8, MAPT, EGFR, HSPA1A, CDC25B |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.769E-07 | 2.524E-06 | PDGFRB, AKT1, BRAF, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.165E-06 | 1.306E-05 | PDGFRB, GSK3B, SMAD3, ERBB2, AKT1, BRAF, MET, EGFR, PTK2, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.039E-06 | 1.255E-05 | GSK3B, ERBB2, AKT1, BRAF, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 3.188E-06 | 3.128E-05 | PDGFRB, AKT1, BRAF, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.617E-06 | 1.693E-05 | INSR, ERBB2, AKT1, TEK, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 3.440E-06 | 3.177E-05 | SMAD3, ERBB2, AKT1, BRAF, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.707E-06 | 3.234E-05 | PDGFRB, ERBB2, AKT1, MET, EGFR |
09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 9.201E-06 | 7.603E-05 | PTPN1, GSK3B, INSR, AKT1, BRAF, PTPRF |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 3.369E-05 | 2.404E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.397E-05 | 1.792E-04 | PLK1, AKT1, BRAF, CDC25B, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 4.003E-05 | 2.733E-04 | PTPN1, GSK3B, INSR, AKT1, PTPRF |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 4.405E-05 | 2.882E-04 | ERBB2, AKT1, BRAF, EGFR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 6.177E-05 | 3.879E-04 | SRC, KDR, AKT1, PTK2 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.264E-05 | 9.919E-05 | SRC, ERBB2, BRAF, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 6.585E-05 | 3.977E-04 | GSK3B, SMAD3, AKT1, BRAF |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 7.461E-05 | 4.339E-04 | INSR, AKT1, HSPA1A, IGF1R |
09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 5.013E-04 | 2.539E-03 | GSK3B, SRC, AKT1, BRAF, PTK2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 4.032E-04 | 2.110E-03 | SRC, AKT1, EGFR, HSPA1A |
09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 9.212E-04 | 4.477E-03 | PDGFRB, SRC, BRAF, PTK2, EGFR |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.120E-04 | 6.281E-04 | SLCO1B1, CA2, SLCO1B3, NR1H4 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.220E-03 | 5.475E-03 | GSK3B, AKT1, BRAF, EGFR |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.325E-03 | 5.780E-03 | GSK3B, CSNK2A1, AKT1, HSPA1A |
09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 9.410E-04 | 4.477E-03 | GSK3B, SMAD3, PLK1, CDC25B |
09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 1.029E-03 | 4.749E-03 | GSK3B, MET, PTK2, EPHB4 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.553E-03 | 6.583E-03 | GSK3B, SMAD3, AKT1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 1.635E-03 | 6.583E-03 | PDGFRB, INSR, AKT1, EGFR |
09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 2.102E-03 | 7.825E-03 | PDGFRB, POLB, GSK3B, SMAD3, AKT1 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 2.360E-03 | 8.422E-03 | PDGFRB, FLT4, KDR, MET, EGFR |
09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 2.863E-03 | 9.732E-03 | BACE1, GSK3B, MAPT, HSD17B10 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.060E-03 | 7.825E-03 | GSK3B, SRC, AKT1 |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.605E-03 | 6.583E-03 | AKT1, BRAF, MET |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.143E-03 | 7.825E-03 | SMAD3, AKT1, BRAF |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.749E-03 | 6.863E-03 | SRC, MET, EGFR |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 2.589E-03 | 9.033E-03 | SRC, MET, PTK2 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.558E-04 | 8.433E-04 | AKR1B10, GAA, AKR1B1 |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.913E-03 | 9.732E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
C00-D49: Neoplasms | AML | NA | KDR; |
C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; TEK; EGFR; SRC; CDC25B; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; INSR; AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; INSR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; EGFR; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; INSR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; EGFR; SRC; |